BDI and Ellison Hold Regular Online Video Meeting... "Information Exchange and Partnership Reconfirmation"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 27th that it discussed plans for the prompt clinical progress of its anticancer pipeline with Ellison Pharmaceuticals (Ellison) and reaffirmed their mutual partnership.

During the recent non-face-to-face video conference, VIDI Chairman Seungman Ahn spoke with Ellison CEO Edwin Thomas and CFO Keith Derrah about the progress of the Phase 3 clinical trial of the pancreatic cancer treatment new drug "Glufosfamide," the Phase 2 clinical trial progress of ILC (lung cancer and pediatric osteosarcoma treatment), and the IPO schedule.

Edwin Thomas, CEO of Ellison, stated, "Due to the impact of COVID-19, human exchanges were halted, inevitably delaying clinical trials. Currently, clinical trials are being conducted only in the United States, but as COVID-19 stabilizes, additional trials will be conducted in Europe and Asia." He added, "Regarding future progress, both companies will closely consult and share information regularly."

Chairman Ahn and Ellison emphasized close communication between the two companies, agreed to hold regular monthly meetings to inform shareholders even of minor issues, and exchanged opinions on exploring ways VIDI can support to ultimately achieve positive results.

Keith Derrah, CFO of Ellison, said, "Ellison’s four pipeline projects are progressing smoothly, and we are in discussions with several investors for additional funding to expedite clinical progress."

He continued, "Ellison’s NASDAQ listing is still under review. The U.S. securities market highly values the technological worth of Ellison’s four pipelines and holds high expectations for the success of the Phase 3 pancreatic cancer clinical trial."

Ellison plans to proceed with the NASDAQ listing through prior consultation with VIDI once a specific schedule is established, emphasizing that additional investment and cooperation from VIDI will be necessary during the NASDAQ listing process.

This content was produced with the assistance of AI translation services.